Synthesis, biological evaluation and molecular docking studies of tetrahydropyrido[3, 4- d ]pyrimidine derivatives as anti-leukemic agents

被引:0
作者
Parashuram, V. [1 ]
Kumari, K. Aruna [2 ]
Mullaguri, Sai Charitha [3 ]
Kancha, Rama Krishna [3 ]
Mittapelli, Vasantha [1 ]
机构
[1] Mahatma Gandhi Univ, Dept Chem, Nalgonda 508254, Telangana, India
[2] Matrusri Engn Coll, Dept Sci & Humanities, Hyderabad 500059, India
[3] Osmania Univ, CPMB, Mol Med & Therapeut Lab, Hyderabad 500007, India
关键词
Pyrido[3,4-d]pyrimidine; Suzuki coupling; Anti-leukaemic activity; Drug resistance; Molecular docking; INHIBITORS; MUTANT; TARGET;
D O I
10.1016/j.rechem.2024.101554
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Substituted tetrahydropyrido[3,4- d ]pyrimidine derivatives ( 2a -l ) have been synthesized through a series of Nsubstitution, Suzuki coupling, deprotection and condensation reactions. The structure of new compounds was analysed by interpretations of FTIR, 1 H NMR, 13 C NMR, and mass spectral data. The synthesised compounds were tested for their anti-leukaemic activity on wild type K562 (K562 -WT) and IR1 and IR2 cell lines that are imatinib resistant due to clonal evolution. The compounds 2b , 2c , 2i , 2k and 8 showed were high HEK293 cells. Molecular docking studies using crystal structure of drug -resistant ABL-T315I mutant revealed the ability of these molecules to overcome resistance due to mutations in the ABL kinase. Notably, experimental and computational analyses identified that compound 8 exhibited highest anti -leukemic activity and potential to overcome drug resistance arising due to multiple molecular mechanisms.
引用
收藏
页数:8
相关论文
共 25 条
[1]   Analysis of cellular models of clonal evolution reveals co-evolution of imatinib and HSP90 inhibitor resistances [J].
Arolla, Rajender Goud ;
Malladi, Shweta ;
Bhaduri, Utsa ;
Gayatri, Meher Bolisetti ;
Pattamshetty, Preethi ;
Mohan, Vasavi ;
Katika, Madhumohan Rao ;
Reddy, Aramati Bindu Madhava ;
Rao, Manchanahalli R. Satyanarayana ;
Vudem, Dashavantha Reddy ;
Kancha, Rama Krishna .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 534 :461-467
[2]   Process development and scale-up of a selective α1-adrenoceptor antagonist [J].
Connolly, TJ ;
Matchett, M ;
Sarma, K .
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2005, 9 (01) :80-87
[3]   Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases [J].
Dasgupta, Yashodhara ;
Koptyra, Mateusz ;
Hoser, Grazyna ;
Kantekure, Kanchan ;
Roy, Darshan ;
Gornicka, Barbara ;
Nieborowska-Skorska, Margaret ;
Bolton-Gillespie, Elisabeth ;
Cerny-Reiterer, Sabine ;
Muschen, Markus ;
Valent, Peter ;
Wasik, Mariusz A. ;
Richardson, Christine ;
Hantschel, Oliver ;
van der Kuip, Heiko ;
Stoklosa, Tomasz ;
Skorski, Tomasz .
BLOOD, 2016, 127 (17) :2131-2143
[4]   Design and synthesis of tetrahydropyridopyrimidine derivatives as dual GPR119 and DPP-4 modulators [J].
Fang, Yuanying ;
Zhang, Shaokun ;
Wu, Wenting ;
Liu, Yanhua ;
Yang, Juan ;
Li, Yuyuan ;
Li, Min ;
Dong, Huanhuan ;
Jin, Yi ;
Liu, Ronghua ;
Yang, Zunhua .
BIOORGANIC CHEMISTRY, 2020, 94
[5]   Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer [J].
Fell, Jay B. ;
Fischer, John P. ;
Baer, Brian R. ;
Blake, James F. ;
Bouhana, Karyn ;
Briere, David M. ;
Brown, Karin D. ;
Burgess, Laurence E. ;
Burns, Aaron C. ;
Burkard, Michael R. ;
Chiang, Harrah ;
Chicarelli, Mark J. ;
Cook, Adam W. ;
Gaudino, John J. ;
Hallin, Jill ;
Hanson, Lauren ;
Hartley, Dylan P. ;
Hicken, Erik J. ;
Hingorani, Gary P. ;
Hinklin, Ronald J. ;
Mejia, Macedonio J. ;
Olson, Peter ;
Otten, Jennifer N. ;
Rhodes, Susan P. ;
Rodriguez, Martha E. ;
Savechenkov, Pavel ;
Smith, Darin J. ;
Sudhakar, Niranjan ;
Sullivan, Francis X. ;
Tang, Tony P. ;
Vigers, Guy P. ;
Wollenberg, Lance ;
Christensen, James G. ;
Marx, Matthew A. .
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (13) :6679-6693
[6]   Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity [J].
Fell, Jay B. ;
Fischer, John P. ;
Baer, Brian R. ;
Ballard, Joshua ;
Blake, James F. ;
Bouhana, Karyn ;
Brandhuber, Barbara J. ;
Briere, David M. ;
Burgess, Laurence E. ;
Burkard, Michael R. ;
Chiang, Harrah ;
Chicarelli, Mark J. ;
Davidson, Kevin ;
Gaudino, John J. ;
Hallin, Jill ;
Hanson, Lauren ;
Hee, Kenneth ;
Hicken, Erik J. ;
Hinklin, Ronald J. ;
Marx, Matthew A. ;
Mejia, Macedonio J. ;
Olson, Peter ;
Savechenkov, Pavel ;
Sudhakar, Niranjan ;
Tang, Tony P. ;
Vigers, Guy P. ;
Zecca, Henry ;
Christensen, James G. .
ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (12) :1230-1234
[7]   Estimates of the cancer incidence and mortality in Europe in 2006 [J].
Ferlay, J. ;
Autier, P. ;
Boniol, M. ;
Heanue, M. ;
Colombet, M. ;
Boyle, P. .
ANNALS OF ONCOLOGY, 2007, 18 (03) :581-592
[8]   Design, synthesis of benzimidazole tethered 3,4-dihydro-2H-benzo[e] [1,3] oxazines as anticancer agents [J].
Gali, Srinivas ;
Raghu, D. ;
Mallikanti, Veerabhadraiah ;
Thumma, Vishnu ;
Vaddiraju, Namratha .
MOLECULAR DIVERSITY, 2024, 28 (03) :1347-1361
[9]   The hallmarks of cancer [J].
Hanahan, D ;
Weinberg, RA .
CELL, 2000, 100 (01) :57-70
[10]   Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors [J].
Inoue, Satoshi ;
Yamane, Yoshinobu ;
Tsukamoto, Shuntaro ;
Murai, Norio ;
Azuma, Hiroshi ;
Nagao, Satoshi ;
Nishibata, Kyoko ;
Fukushima, Sayo ;
Ichikawa, Kenji ;
Nakagawa, Takayuki ;
Sugi, Naoko Hata ;
Ito, Daisuke ;
Kato, Yu ;
Goto, Aya ;
Kakiuchi, Dai ;
Ueno, Takashi ;
Matsui, Junji ;
Matsushima, Tomohiro .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 48